Bluebird Bio on brink of turning science fiction into reality, European head says

Where US biotech bluebird bio (Nasdaq: BLUE) is concerned, comparisons can easily be drawn with the gene therapy field as a whole.

There has been a lot of promise and excitement among the scientific and investor communities over a period of decades, but for the most part, patients are still waiting for the products that will change or save their lives.

Since Bluebird has been around since 1992 and claims to be the leader of the gene therapy revolution, it is not surprising that questions are starting to arise on when its pipeline will actually deliver the products that it has long promised for patients with severe genetic and rare diseases and cancer, especially when other big names in this space have scored US approvals for their gene therapies in recent months.